文献速递胸部肿瘤

局部晚期非小细胞肺癌前瞻性多中心放疗试验后心脏事件的合并分析

Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2017-03-16

该研究合并分析2004至2013年两个中心四项前瞻性放疗试验中125例II至III期非小细胞肺癌患者,中位随访51个月,24个月≥3级心脏事件累积发生率为11%(95%CI 5%至16%),原有心脏病和较高心脏平均剂量与≥3级心脏事件显著相关。

要点

  • 125例局部晚期NSCLC患者放疗后24个月≥3级心脏事件累积发生率为11%(95%CI 5%至16%)。
  • 原有心脏病(HR 2.96;95%CI 1.07至8.21;P=.04)和心脏平均剂量(HR 1.07/Gy;95%CI 1.02至1.13/Gy;P=.01)与≥3级心脏事件显著相关。
  • 疾病进展(HR 2.15;95%CI 1.54至3.00)和≥3级心脏事件(HR 1.76;95%CI 1.04至2.99)均与总生存下降相关。

核心结论

  • 局部晚期NSCLC根治性放疗后24个月≥3级心脏事件累积发生率超过10%,原有心脏病和较高心脏平均剂量与较高心脏事件率显著相关,作者建议谨慎对待心脏剂量以最小化放疗相关损伤风险,但需权衡肿瘤控制。

研究设计与样本

  • 研究纳入2004至2013年两个中心四项前瞻性放疗试验中II至III期NSCLC患者,所有心脏事件按CTCAE v4.03分级,主要终点为≥3级心脏事件。

主要发现

  • 125例患者符合标准,中位随访51个月(存活患者),中位处方剂量70 Gy,84%接受同步化疗,27%有原有心脏病。
  • 19例发生≥3级心脏事件,中位发生时间11个月(四分位距6至24个月),24个月累积发生率11%(95%CI 5%至16%)。
  • 多变量分析中,原有心脏病(HR 2.96;95%CI 1.07至8.21;P=.04)和心脏平均剂量(HR 1.07/Gy;95%CI 1.02至1.13/Gy;P=.01)与≥3级心脏事件显著相关。
  • 作为时间依赖变量,疾病进展(HR 2.15;95%CI 1.54至3.00)和≥3级心脏事件(HR 1.76;95%CI 1.04至2.99)与总生存下降相关,疾病进展(n=71)较≥3级心脏事件(n=19)更常见。

临床怎么用

  • 作者认为,应谨慎对待心脏剂量以最小化放疗相关损伤风险,但鉴于疾病进展的不良预后,心脏风险应与肿瘤控制相平衡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Radiation therapy is a critical component in the care of patients with non-small-cell lung cancer (NSCLC), yet cardiac injury after treatment is a significant concern. Therefore, we wished to elucidate the incidence of cardiac events and their relationship to radiation dose to the heart. Patients and Materials Study eligibility criteria included patients with stage II to III NSCLC treated on one of four prospective radiation therapy trials at two centers from 2004 to 2013. All cardiac events were reviewed and graded per Common Terminology Criteria for Adverse Events (v4.03). The primary end point was the development of a grade ≥ 3 cardiac event. Results In all, 125 patients met eligibility criteria; median follow-up was 51 months for surviving patients. Median prescription dose was 70 Gy, 84% received concurrent chemotherapy, and 27% had pre-existing cardiac disease. Nineteen patients had a grade ≥ 3 cardiac event at a median of 11 months (interquartile range, 6 to 24 months), and 24-month cumulative incidence was 11% (95% CI, 5% to 16%). On multivariable analysis (MVA), pre-existing cardiac disease (hazard ratio [HR], 2.96; 95% CI, 1.07 to 8.21; P = .04) and mean heart dose (HR, 1.07/Gy; 95% CI, 1.02 to 1.13/Gy; P = .01) were significantly associated with grade ≥ 3 cardiac events. Analyzed as time-dependent variables on MVA analysis, both disease progression (HR, 2.15; 95% CI, 1.54 to 3.00) and grade ≥ 3 cardiac events (HR, 1.76; 95% CI, 1.04 to 2.99) were associated with decreased overall survival. However, disease progression (n = 71) was more common than grade ≥ 3 cardiac events (n = 19). Conclusion The 24-month cumulative incidence of grade ≥ 3 cardiac events exceeded 10% among patients with locally advanced NSCLC treated with definitive radiation. Pre-existing cardiac disease and higher mean heart dose were significantly associated with higher cardiac event rates. Caution should be used with cardiac dose to minimize risk of radiation-associated injury. However, cardiac risks should be balanced against tumor control, given the unfavorable prognosis associated with disease progression.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dess RT, Sun Y, Matuszak MM, et al. Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2017. PMID: 28301264. doi:10.1200/JCO.2016.71.6142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。